JP2024545981A - 経口投与のための組成物および方法 - Google Patents

経口投与のための組成物および方法 Download PDF

Info

Publication number
JP2024545981A
JP2024545981A JP2023574593A JP2023574593A JP2024545981A JP 2024545981 A JP2024545981 A JP 2024545981A JP 2023574593 A JP2023574593 A JP 2023574593A JP 2023574593 A JP2023574593 A JP 2023574593A JP 2024545981 A JP2024545981 A JP 2024545981A
Authority
JP
Japan
Prior art keywords
polypeptide
polypeptide construct
construct
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023574593A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023108126A5 (https=
JP2024545981A5 (https=
Inventor
タイ、ゴック
ポレット、ジョナサン
Original Assignee
イマジン ファーマ、エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イマジン ファーマ、エルエルシー filed Critical イマジン ファーマ、エルエルシー
Publication of JP2024545981A publication Critical patent/JP2024545981A/ja
Publication of JPWO2023108126A5 publication Critical patent/JPWO2023108126A5/ja
Publication of JP2024545981A5 publication Critical patent/JP2024545981A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)
JP2023574593A 2021-12-11 2022-12-09 経口投与のための組成物および方法 Pending JP2024545981A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163288579P 2021-12-11 2021-12-11
US63/288,579 2021-12-11
PCT/US2022/081277 WO2023108126A1 (en) 2021-12-11 2022-12-09 Compositions and methods for oral administration

Publications (3)

Publication Number Publication Date
JP2024545981A true JP2024545981A (ja) 2024-12-17
JPWO2023108126A5 JPWO2023108126A5 (https=) 2026-01-28
JP2024545981A5 JP2024545981A5 (https=) 2026-01-28

Family

ID=86731317

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023574593A Pending JP2024545981A (ja) 2021-12-11 2022-12-09 経口投与のための組成物および方法

Country Status (11)

Country Link
US (1) US20250388638A1 (https=)
EP (1) EP4444352A4 (https=)
JP (1) JP2024545981A (https=)
KR (1) KR20240141165A (https=)
CN (1) CN118613284A (https=)
AU (1) AU2022405604A1 (https=)
CA (1) CA3235948A1 (https=)
IL (1) IL312382A (https=)
MX (1) MX2024007105A (https=)
WO (1) WO2023108126A1 (https=)
ZA (1) ZA202404443B (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US20070042392A1 (en) * 2000-02-03 2007-02-22 Nuvelo, Inc. Novel nucleic acids and polypeptides
KR100944034B1 (ko) * 2007-04-19 2010-02-24 한올제약주식회사 프로테아제-내성 폴리펩티드의 경구 투여 제형
KR102497242B1 (ko) * 2016-11-13 2023-02-09 이매진 파마 당뇨병, 고혈압 및 고콜레스테롤혈증을 치료하기 위한 조성물 및 방법
PL3746111T3 (pl) * 2018-02-02 2024-01-15 Novo Nordisk A/S Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową

Also Published As

Publication number Publication date
WO2023108126A9 (en) 2023-08-24
CA3235948A1 (en) 2023-06-15
MX2024007105A (es) 2024-06-24
EP4444352A4 (en) 2025-12-17
KR20240141165A (ko) 2024-09-25
WO2023108126A1 (en) 2023-06-15
AU2022405604A2 (en) 2024-07-11
IL312382A (en) 2024-06-01
ZA202404443B (en) 2025-10-29
US20250388638A1 (en) 2025-12-25
AU2022405604A1 (en) 2024-06-13
CN118613284A (zh) 2024-09-06
EP4444352A1 (en) 2024-10-16

Similar Documents

Publication Publication Date Title
CN101389650B (zh) 包含酰化胰岛素和锌的组合物以及制备所述组合物的方法
JP6416106B2 (ja) ゴナドトロピンカルボキシ末端ペプチドに結合することによりポリペプチドの流体力学的体積を増加させる方法
EP1611093B1 (en) Modified transferrin fusion proteins
US9074015B2 (en) Recombinantly expressed insulin polypeptides and uses thereof
US20140364362A1 (en) Therapeutic agents comprising insulin amino acid sequences
US20220275029A1 (en) Compositions and particles for payload delivery
CN104010650A (zh) 长效生长激素及其生产方法
US20150361154A1 (en) Therapeutic agents, compositions, and methods for glycemic control
CN102389413A (zh) 用于治疗糖尿病的组合物及其应用
Lee et al. Genetic engineering of novel super long-acting Exendin-4 chimeric protein for effective treatment of metabolic and cognitive complications of obesity
EP3442562B1 (en) An il-22 dimer for use in treating necrotizing enterocolitis
CN111194223B (zh) 与白蛋白具有较佳结合亲和力的药物分子
KR20230039594A (ko) 경구 펩티드 투여
US10765757B2 (en) Mucosal delivery of therapeutic molecules, proteins, or particles coupled to ceramide lipids
JP2024545981A (ja) 経口投与のための組成物および方法
US20190160152A1 (en) Long-acting oxyntomodulin formulation and methods of producing and administering same
HK40109249A (zh) 用於口服给予的组合物和方法
US20260116928A1 (en) Compositions and particles for payload delivery
WO2025117857A2 (en) Adp-ribosylation factor compositions and methods of use thereof
TW202535451A (zh) 經修飾之調酸素及其使用方法
Zhang et al. Exendin-4 and Its Derivatives for Diabetes and Obesity: Old Story and New Hope
NZ622174A (en) Glucagon-like peptide-2 compositions and methods of making and using same
NZ622174B2 (en) Glucagon-like peptide-2 compositions and methods of making and using same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251208